Unique ID issued by UMIN | UMIN000021086 |
---|---|
Receipt number | R000024324 |
Scientific Title | A comparison of the additive efficacy of Umeclidinium bromide on fluticasone furoate/vilanterole in asthma-COPD overlap syndrome. |
Date of disclosure of the study information | 2016/03/01 |
Last modified on | 2017/02/23 15:56:56 |
A comparison of the additive efficacy of Umeclidinium bromide on fluticasone furoate/vilanterole in asthma-COPD overlap syndrome.
Additive effect of Umeclidinium bromide on fluticasone furoate/vilanterole in asthma-COPD overlap syndrome.
A comparison of the additive efficacy of Umeclidinium bromide on fluticasone furoate/vilanterole in asthma-COPD overlap syndrome.
Additive effect of Umeclidinium bromide on fluticasone furoate/vilanterole in asthma-COPD overlap syndrome.
Japan |
asthma-COPD overlap syndrome
Pneumology |
Others
NO
To compare the additive effect of Umeclidinium bromide on fluticasone furoate/vilanterole in patients with asthma-COPD overlap syndrome
Efficacy
Improvement of respiratory functions
Improvement of quality of life
Interventional
Cross-over
Randomized
Individual
Single blind -investigator(s) and assessor(s) are blinded
Active
YES
YES
2
Treatment
Medicine | Other |
Additive admionistration of Umeclidinium bromide on fluticasone furoate/vilanterole in patients with asthma-COPD overlap syndrome
Patients are divided in 2 groups. In group A, firstly 4 week treatment of Umeclidinium bromide and fluticasone furoate/vilanterole, next 4 weeks only fluticasone furoate/vilanterole. In B group, firstly 4 week treatment of only fluticasone furoate/vilanterole, next 4 weeks Umeclidinium bromide and fluticasone furoate/vilanterole are administered. Respiratory functions and were evalueted before and each treatment periods.
Additive admionistration of Umeclidinium bromide on fluticasone furoate/vilanterole in patients with asthma-COPD overlap syndrome
Patients are divided in 2 groups. In group A, firstly 4 week treatment of Umeclidinium bromide and fluticasone furoate/vilanterole, next 4 weeks only fluticasone furoate/vilanterole. In B group, firstly 4 week treatment of only fluticasone furoate/vilanterole, next 4 weeks Umeclidinium bromide and fluticasone furoate/vilanterole are administered. QOL scores are evalueted before and each treatment periods.
16 | years-old | <= |
90 | years-old | >= |
Male and Female
stable asthma-COPD overlap syndrome
unstable asthma-COPD overlap syndrome
20
1st name | |
Middle name | |
Last name | Yoshihisa Ishiura |
Toyama City Hospital
Respiratory Medicine
2-1 Imaizumi-Hokubu-machi, Toyama City Toyama, Jappan
076-422-1112
ishiura@tch.toyama.toyama.jp
1st name | |
Middle name | |
Last name | Yoshihisa Ishiura |
Toyama City Hospital
Respiratory Medicine
2-1 Imaizumi-Hokubu-machi, Toyama City Toyama, Jappan
076-422-1112
ishiura@tch.toyama.toyama.jp
Respiratory Medicine of Toyama City Hospital
Respiratory Medicine of Toyama City Hospital
Local Government
NO
2016 | Year | 03 | Month | 01 | Day |
Unpublished
Preinitiation
2016 | Year | 02 | Month | 01 | Day |
2016 | Year | 03 | Month | 01 | Day |
2016 | Year | 02 | Month | 18 | Day |
2017 | Year | 02 | Month | 23 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000024324
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |